In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 662 ( 2022-09-14)
Kurzfassung:
Drug-resistant Gram-positive bacterial infections remain a critical concern, and new treatment modalities against them are needed in the clinic. Blaskovich et al. optimized a vancomycin-derived antibiotic bearing a membrane-targeting glycopeptide and demonstrated that this compound was effective in multiple mouse models of Gram-positive infections, including difficult-to-treat biofilms. The optimized compound was more potent than its parent, vancomycin, and had a low rate of resistance, suggesting that this candidate compound may warrant further development.
Materialart:
Online-Ressource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abj2381
Sprache:
Englisch
Verlag:
American Association for the Advancement of Science (AAAS)
Publikationsdatum:
2022
